Hangzhou Tigermed ConsultingLtd
Market Cap
CN¥120.9b
Last Updated
2021/02/28 09:05 UTC
Data Sources
Company Financials +
Executive Summary
Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization in China and internationally. More Details
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Hangzhou Tigermed ConsultingLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 300347 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 300347's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
-23.5%
300347
-16.4%
CN Life Sciences
-6.4%
CN Market
1 Year Return
83.8%
300347
88.3%
CN Life Sciences
26.5%
CN Market
Return vs Industry: 300347 underperformed the CN Life Sciences industry which returned 88.3% over the past year.
Return vs Market: 300347 exceeded the CN Market which returned 26.5% over the past year.
Shareholder returns
| 300347 | Industry | Market | |
|---|---|---|---|
| 7 Day | -23.5% | -16.4% | -6.4% |
| 30 Day | -16.0% | -11.7% | -1.8% |
| 90 Day | 23.3% | 31.6% | 2.8% |
| 1 Year | 84.4%83.8% | 88.9%88.3% | 28.5%26.5% |
| 3 Year | 447.1%440.7% | 264.0%259.8% | 27.9%21.6% |
| 5 Year | 651.1%637.3% | 257.2%251.2% | 44.1%34.1% |
Long-Term Price Volatility Vs. Market
How volatile is Hangzhou Tigermed ConsultingLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Hangzhou Tigermed ConsultingLtd undervalued compared to its fair value and its price relative to the market?
66x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 300347 (CN¥140.58) is trading above our estimate of fair value (CN¥89.55)
Significantly Below Fair Value: 300347 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 300347 is good value based on its PE Ratio (66x) compared to the CN Life Sciences industry average (92.7x).
PE vs Market: 300347 is poor value based on its PE Ratio (66x) compared to the CN market (34.1x).
Price to Earnings Growth Ratio
PEG Ratio: 300347 is poor value based on its PEG Ratio (6.4x)
Price to Book Ratio
PB vs Industry: 300347 is overvalued based on its PB Ratio (7.7x) compared to the CN Life Sciences industry average (7x).
Next Steps
Future Growth
How is Hangzhou Tigermed ConsultingLtd forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
10.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300347's forecast earnings growth (10.3% per year) is above the savings rate (3.3%).
Earnings vs Market: 300347's earnings (10.3% per year) are forecast to grow slower than the CN market (24.8% per year).
High Growth Earnings: 300347's earnings are forecast to grow, but not significantly.
Revenue vs Market: 300347's revenue (22.6% per year) is forecast to grow faster than the CN market (18.3% per year).
High Growth Revenue: 300347's revenue (22.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300347's Return on Equity is forecast to be low in 3 years time (12.5%).
Next Steps
Past Performance
How has Hangzhou Tigermed ConsultingLtd performed over the past 5 years?
49.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 300347 has a high level of non-cash earnings.
Growing Profit Margin: 300347's current net profit margins (53.1%) are higher than last year (25%).
Past Earnings Growth Analysis
Earnings Trend: 300347's earnings have grown significantly by 49.8% per year over the past 5 years.
Accelerating Growth: 300347's earnings growth over the past year (138.5%) exceeds its 5-year average (49.8% per year).
Earnings vs Industry: 300347 earnings growth over the past year (138.5%) exceeded the Life Sciences industry 34.4%.
Return on Equity
High ROE: 300347's Return on Equity (10.3%) is considered low.
Next Steps
Financial Health
How is Hangzhou Tigermed ConsultingLtd's financial position?
Financial Position Analysis
Short Term Liabilities: 300347's short term assets (CN¥12.5B) exceed its short term liabilities (CN¥899.5M).
Long Term Liabilities: 300347's short term assets (CN¥12.5B) exceed its long term liabilities (CN¥403.8M).
Debt to Equity History and Analysis
Debt Level: 300347's debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: 300347's debt to equity ratio has reduced from 17.6% to 0.1% over the past 5 years.
Debt Coverage: 300347's debt is well covered by operating cash flow (2976.1%).
Interest Coverage: 300347 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Hangzhou Tigermed ConsultingLtd current dividend yield, its reliability and sustainability?
0.20%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 300347's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.4%).
High Dividend: 300347's dividend (0.2%) is low compared to the top 25% of dividend payers in the CN market (1.8%).
Stability and Growth of Payments
Stable Dividend: 300347 is not paying a notable dividend for the CN market, therefore no need to check if payments are stable.
Growing Dividend: 300347 is not paying a notable dividend for the CN market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 300347 is not paying a notable dividend for the CN market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 300347's dividend in 3 years as they are not forecast to pay a notable one for the CN market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Xiaochun Cao (51 yo)
1.83yrs
Tenure
CN¥784,100
Compensation
Dr. Xiaochun Cao, M.D., serves as Consultant at TigerYeah Capital. She co-founded Hangzhou Tigermed Consulting Co., Ltd. and serves as President since 2019 also its General Manager since April 25, 2019. Dr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 2.08yrs | CN¥818.20k | 20.31% CN¥ 24.6b | |
| Co-Founder | 1.83yrs | CN¥784.10k | 6.55% CN¥ 7.9b | |
| Senior VP of Investment | 4.17yrs | CN¥1.67m | no data | |
| Deputy GM & Non-Independent Director | 6.92yrs | CN¥753.40k | 1.18% CN¥ 1.4b | |
| Head of Accounting Department | no data | no data | no data | |
| Vice President of Human Resources & Field Service | 3.17yrs | no data | no data | |
| VP, Head of Data Resources Department & Member of Supervisory Board | 3.67yrs | no data | 1.42% CN¥ 1.7b | |
| Chief Biostatistician | 4yrs | no data | no data | |
| Senior Vice President of Biometrics | no data | no data | no data | |
| Partner | no data | no data | no data | |
| Senior VP of CMC & Biological Analysis Business Line | 4yrs | no data | no data | |
| VP & Head of International Business | 4.25yrs | no data | no data |
4.0yrs
Average Tenure
53yo
Average Age
Experienced Management: 300347's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 2.08yrs | CN¥818.20k | 20.31% CN¥ 24.6b | |
| Co-Founder | 1.83yrs | CN¥784.10k | 6.55% CN¥ 7.9b | |
| Deputy GM & Non-Independent Director | 6.92yrs | CN¥753.40k | 1.18% CN¥ 1.4b | |
| VP, Head of Data Resources Department & Member of Supervisory Board | 3.67yrs | no data | 1.42% CN¥ 1.7b | |
| Non-Employee Supervisory | 0.83yr | CN¥72.00k | no data | |
| Independent Director | 0.83yr | no data | no data | |
| Non-Employee Supervisor | 0.83yr | CN¥96.00k | no data | |
| Independent Director | 3.5yrs | CN¥96.00k | no data | |
| Independent Director | 0.83yr | no data | no data |
2.1yrs
Average Tenure
55yo
Average Age
Experienced Board: 300347's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.4%.
Top Shareholders
Company Information
Hangzhou Tigermed Consulting Co.,Ltd's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Hangzhou Tigermed Consulting Co.,Ltd
- Ticker: 300347
- Exchange: SZSE
- Founded: 2004
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥120.942b
- Shares outstanding: 872.48m
- Website: https://tigermedgrp.com
Number of Employees
Location
- Hangzhou Tigermed Consulting Co.,Ltd
- No. 19 Jugong Road
- Room 2001-2010, 20th Floor
- Hangzhou
- Zhejiang Province
- 310053
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 300347 | SZSE (Shenzhen Stock Exchange) | Yes | Domestic Shares | CN | CNY | Aug 2012 |
| 300347 | XSEC (Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect) | Yes | Domestic Shares | CN | CNY | Aug 2012 |
| 3347 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Foreign Shares-Foreign Listed | HK | HKD | Aug 2020 | |
| 3347 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Foreign Shares-Foreign Listed | HK | HKD | Aug 2020 | |
| 3347 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Foreign Shares-Foreign Listed | HK | HKD | Aug 2020 |
Biography
Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization in China and internationally. The company offers regulatory submission and approval, medical translation, and good manufa...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/28 09:05 |
| End of Day Share Price | 2021/02/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.